Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
- PMID: 3591690
- DOI: 10.1016/0002-9149(87)90918-0
Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Abstract
To determine whether oral milrinone therapy has an effect on complex ventricular arrhythmias in patients with severe congestive heart failure and, if so, whether a change in the severity of complex ventricular arrhythmias after 1 week of milrinone therapy is associated with a change in the mode or frequency of cardiac mortality, a retrospective analysis was performed to determine the frequency of ventricular tachycardia and the density of ventricular couplets on 24-hour ambulatory electrocardiographic recordings performed before and 1 week after initiation of oral milrinone therapy in 74 consecutive patients with New York Heart Association functional class III or IV congestive heart failure. The endpoints of mortality and mode of death were assessed during a mean follow-up of 6 months. In 91% of the patients, 1 week of oral milrinone therapy was associated with no significant change (85%) or a significant decrease (6%) in the density of ventricular couplets and frequency of ventricular tachycardia. However, in 9% of patients the frequency of complex ventricular arrhythmias increased significantly at the end of 1 week of oral milrinone therapy. In this subgroup, neither total cardiac mortality nor the incidence of sudden cardiac death was significantly higher than that in patients with no change or a decrease in complex ventricular ectopic activity.
Similar articles
-
Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias.Am Heart J. 1985 Oct;110(4):800-6. doi: 10.1016/0002-8703(85)90460-0. Am Heart J. 1985. PMID: 4050652
-
Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.Am J Cardiol. 1987 Jun 1;59(15):1345-50. doi: 10.1016/0002-9149(87)90917-9. Am J Cardiol. 1987. PMID: 3591689 Clinical Trial.
-
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.Am J Cardiol. 2000 May 15;85(10):1207-11. doi: 10.1016/s0002-9149(00)00729-3. Am J Cardiol. 2000. PMID: 10802002 Clinical Trial.
-
Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias.Pacing Clin Electrophysiol. 1993 May;16(5 Pt 1):1051-9. doi: 10.1111/j.1540-8159.1993.tb04579.x. Pacing Clin Electrophysiol. 1993. PMID: 7685884 Review.
-
Why patients with congestive heart failure die: arrhythmias and sudden cardiac death.Circulation. 1987 May;75(5 Pt 2):IV28-35. Circulation. 1987. PMID: 3552300 Review.
Cited by
-
Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.Drugs. 1992 Dec;44(6):928-45. doi: 10.2165/00003495-199244060-00003. Drugs. 1992. PMID: 1282864 Review.
-
Milrinone. A preliminary review of its pharmacological properties and therapeutic use.Drugs. 1988 Aug;36(2):158-92. doi: 10.2165/00003495-198836020-00003. Drugs. 1988. PMID: 3053125 Review.
-
Phosphodiesterase III inhibitors: long-term risks and short-term benefits.Cardiovasc Drugs Ther. 1993 Aug;7(4):655-60. doi: 10.1007/BF00877818. Cardiovasc Drugs Ther. 1993. PMID: 8241008 Review.
-
OPC-8212 in the treatment of congestive heart failure: results of a pilot study.Cardiovasc Drugs Ther. 1988 Dec;2(5):653-60. doi: 10.1007/BF00054205. Cardiovasc Drugs Ther. 1988. PMID: 3154640
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical